8-K: Candel Therapeutics Announces Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer, Set for Oral Presentation at ASCO 2025

Candel Therapeutics will present positive Phase 3 clinical trial data for CAN-2409 in localized prostate cancer at the ASCO 2025 Annual Meeting.

Summary

• Candel Therapeutics announced that an abstract featuring data from its Phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer has been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
• The presentation will take place on June 3, 2025, in Chicago, IL.
• CAN-2409 is an investigational multimodal biological immunotherapy designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient's tumor, inducing an immune response.
• In December 2024, Candel announced that CAN-2409 achieved its primary endpoint in the Phase 3 trial, demonstrating a statistically significant and clinically meaningful improvement in disease-free survival when added to standard-of-care radiation therapy +/androgen deprivation therapy.
• A Phase 2a clinical trial of CAN-2409 in borderline resectable PDAC showed an estimated median overall survival of 31.4 months after experimental treatment with CAN-2409 plus SoC versus 12.5 months in the control group in patients with PDAC who only received SoC.
• Final survival data from a Phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC showed an mOS of 24.5 months in 46 evaluable patients receiving 2 courses of CAN-2409.
• CAN-2409 has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC, and localized prostate cancer.
• The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
• CAN-3110 is in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG) and initial results showed nearly two-fold increase in median overall survival compared to historical controls after a single CAN-3110 injection.

Sentiment

Score: 8

Explanation: The document highlights positive Phase 3 results and FDA designations, indicating a favorable outlook for Candel Therapeutics and its lead product candidate, CAN-2409. The promising data from Phase 2a trials in other cancer types further boosts the positive sentiment.

Positives

• Positive Phase 3 results for CAN-2409 in localized prostate cancer, demonstrating improved disease-free survival.
• Promising Phase 2a data for CAN-2409 in PDAC and NSCLC, showing improved survival rates.
• FDA Fast Track Designation for CAN-2409 in multiple cancer types.
• FDA Orphan Drug Designation for CAN-2409 in PDAC.
• CAN-3110 is in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG) and initial results showed nearly two-fold increase in median overall survival compared to historical controls after a single CAN-3110 injection.

Risks

• The press release includes forward-looking statements that are subject to risks and uncertainties.
• Final data from pre-clinical studies and clinical trials may differ materially from reported interim data.
• The company's ability to obtain and maintain regulatory approval of product candidates is subject to risk.
• The company's ability to maintain its intellectual property is subject to risk.

Future Outlook

The company anticipates further data releases and key data readout milestones and presentations, with expectations regarding early biological readouts as predictors of clinical response and the therapeutic benefit of its programs.

Industry Context

This announcement positions Candel Therapeutics among companies developing novel immunotherapies for cancer treatment, particularly in prostate cancer, PDAC, and NSCLC, contributing to the growing field of multimodal biological immunotherapies.

Comparison to Industry Standards

• The reported median overall survival of 31.4 months in PDAC patients treated with CAN-2409 plus SoC compares favorably to historical SoC benchmarks, which typically range from 11-13 months.
• For NSCLC, the mOS of 24.5 months in patients receiving CAN-2409 is competitive with other immunotherapy combinations, such as checkpoint inhibitors combined with chemotherapy, which often show mOS in the range of 18-22 months.
• The success of CAN-2409 in localized prostate cancer aligns with the industry's focus on improving disease-free survival through novel therapeutic approaches.

Stakeholder Impact

• Positive results could lead to improved treatment options for patients with localized prostate cancer, PDAC, and NSCLC.
• Successful development and commercialization of CAN-2409 could increase shareholder value.
• Positive clinical trial outcomes may enhance the company's reputation and attract potential partners or investors.

Next Steps

• Oral presentation of CAN-2409 data at the ASCO 2025 Annual Meeting on June 3, 2025.
• Release of full abstracts by ASCO on May 22, 2025.
• Continued clinical development of CAN-2409 and CAN-3110.
• Further data analysis and potential regulatory submissions.

Key Dates

Keywords

CAN-2409, Candel Therapeutics, Prostate Cancer, ASCO 2025, Phase 3 Clinical Trial, Immunotherapy, PDAC, NSCLC, CAN-3110, rHGG